Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Brassat

Showing results (21-30 of 94) with videos related to

Pageof 10
Sort By:
Journal of the Neurological Sciences|July 4, 2014
A central nervous system B-cell lymphoma arising two years after initial diagnosis of CLIPPERSGuillaume Taieb, Emmanuelle Uro-Coste, Michel Clanet, et al.
Journal of the Neurological Sciences|August 20, 2016
Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disordersChristine Lebrun, Mikael Cohen, Beatrice Pignolet, et al.
Archives of Neurology|July 15, 2009
Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patientsChristine Lebrun, Caroline Bensa, Marc Debouverie, et al.
Multiple Sclerosis and Related Disorders|January 18, 2019
Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD)Sandra Vukusic, David Brassat, Jerome de Seze, et al.
Multiple Sclerosis and Related Disorders|April 8, 2019
Paraneoplastic neuromyelitis optica and ovarian teratoma: A case seriesRaphaël Bernard-Valnet, Alvaro Cobo-Calvo, Aurore Siegfried, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 9, 2009
Differential impact of the CD45 juxtamembrane wedge on central and peripheral T cell receptor responsesMichelle L Hermiston, Julie Zikherman, Allison L Tan, et al.
Archives of Neurology|January 16, 2008
Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosisEsther Byun, Stacy J Caillier, Xavier Montalban, et al.
Pharmacogenomics|May 20, 2009
United Europeans for development of pharmacogenomics in multiple sclerosis networkKoen Vandenbroeck, Manuel Comabella, Eva Tolosa, et al.
Clinical Neuroradiology|May 31, 2019
What is the Relevance of the Systematic Use of Gadolinium During the MRI Follow-Up of Multiple Sclerosis Patients Under Natalizumab?Guillaume Bellanger, Damien Biotti, Sofia Patsoura, et al.
Plos One|December 10, 2016
Geographical Heterogeneity of Multiple Sclerosis Prevalence in FranceDiane Pivot, Marc Debouverie, Michel Grzebyk, et al.
Pageof 10

Showing results (21-30 of 94) with videos related to

Sort By:
Pageof 10
Journal of the Neurological Sciences|July 4, 2014
A central nervous system B-cell lymphoma arising two years after initial diagnosis of CLIPPERSGuillaume Taieb, Emmanuelle Uro-Coste, Michel Clanet, et al.
Journal of the Neurological Sciences|August 20, 2016
Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disordersChristine Lebrun, Mikael Cohen, Beatrice Pignolet, et al.
Archives of Neurology|July 15, 2009
Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patientsChristine Lebrun, Caroline Bensa, Marc Debouverie, et al.
Multiple Sclerosis and Related Disorders|January 18, 2019
Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD)Sandra Vukusic, David Brassat, Jerome de Seze, et al.
Multiple Sclerosis and Related Disorders|April 8, 2019
Paraneoplastic neuromyelitis optica and ovarian teratoma: A case seriesRaphaël Bernard-Valnet, Alvaro Cobo-Calvo, Aurore Siegfried, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 9, 2009
Differential impact of the CD45 juxtamembrane wedge on central and peripheral T cell receptor responsesMichelle L Hermiston, Julie Zikherman, Allison L Tan, et al.
Archives of Neurology|January 16, 2008
Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosisEsther Byun, Stacy J Caillier, Xavier Montalban, et al.
Pharmacogenomics|May 20, 2009
United Europeans for development of pharmacogenomics in multiple sclerosis networkKoen Vandenbroeck, Manuel Comabella, Eva Tolosa, et al.
Clinical Neuroradiology|May 31, 2019
What is the Relevance of the Systematic Use of Gadolinium During the MRI Follow-Up of Multiple Sclerosis Patients Under Natalizumab?Guillaume Bellanger, Damien Biotti, Sofia Patsoura, et al.
Plos One|December 10, 2016
Geographical Heterogeneity of Multiple Sclerosis Prevalence in FranceDiane Pivot, Marc Debouverie, Michel Grzebyk, et al.
Pageof 10